circRNA basic information
circBase ID: hsa_circ_0000110
Name: hsa_circ_PTPN22
Synonym: circPTPN22
Host Gene: PTPN22
Genomic location(hg19): chr1:114372213-114377061:-
Genomic location(hg38): chr1:113829591-113834439:-
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0001056
MONDO name: gastric cancer
Disease details: gastric cancer
Disease DO ID:
 10534
Disease MeSH ID:
 -
Disease NCIt ID:
 C9331
Disease ICD11 ID:
 1397617262
Disease OMIM ID:
 613659
Species: Human
Species details: Homo sapiens
Tissue specimen:

GC tissues; adjacent non-tumor tissues; plasma
Cell lines:

MKN-1; MKN-45; BGC-823; MGC-803; SGC-7901; HGC-27; AGS; GES-1
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: E-cad, N-cad, Vimentin, Snail, PPP2R2A
Associated microRNA: has_miR_665, has_miR_659, has_miR_513a_3p, has_miR_653, has_miR_1292, has_miR_31, has_miR_1253, has_miR_625, has_miR_924, has_miR_651
Biological function: Promotes GC cell proliferation, migration, invasion, tumor growth and metastasis; facilitates EMT process.
Molecular mechanism: May act as a ceRNA by competitively binding miRNAs (notably has_miR_665), thereby modulating EMT-related markers (E-cad up, N-cad/Vimentin/Snail down upon knockdown).
Biological pathway or process:

EMT (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (other)
Detected method:
Q
S
Validation methods:

circRNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Agarose gel electrophoresis; Clinical Sample Validation; ROC Analysis; Survival Analysis; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Western Blot; In Vivo Animal Model
Clinical significance:

Up-regulated in GC tissues/cells/plasma, shows good diagnostic efficacy (ROC AUC 0.857 in plasma vs healthy donors) and can predict prognosis; low-expression group has higher survival rate; expression decreases after surgery in the same patient.
Description:

circPTPN22 is significantly up-regulated in gastric cancer tissues, cells, and patient plasma and correlates with lymph node metastasis and worse survival. Functionally, circPTPN22 promotes proliferation, migration/invasion and tumor growth; its knockdown suppresses EMT marker changes (E-cad up, N-cad/Vimentin/Snail down). The study suggests circPTPN22 may act via a predicted ceRNA mechanism by binding multiple miRNAs (e.g., has_miR_665), supporting its diagnostic/prognostic biomarker potential.
Confidence score:

0.7947
Other information
Title:

As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway.

Journal: Cancer cell international
Published: 2021
PubMed ID: 33430866
Study type:

combined biological and clinical study
Data availability: All datasets presented in this study are included in the article/additional files.
Code availability: -